URInary peptidomic patterns of Long-COVID syndrome

Important results from the project

The goals we set from the start have been met. The UriCoV project investigated PASC (post-acute sequelae of COVID-19) by identifying urine-based biomarkers to predict risk and distinguish PASC from similar conditions. Three biomarker-based tests were developed. Interviews with sufferers revealed major life challenges and gender differences. PASC leads to reduced quality of life and increased societal costs. UriCoV supports early detection and personalized care.

Expected long term effects

UriCoV addresses the need for unbiased assessment and personalized PASC care using urine proteomic profiles and clinical data. A systems biology approach enabled development of a PASC risk classifier with direct clinical impact. Molecular changes linked to PASC were identified, pointing to targets for intervention. The solution may reduce PASC burden through biomarker-guided treatment and support policy and investment decisions due to its potential health and economic benefit.

Approach and implementation

The project is on schedule and no deviations have occurred. UriCoV developed three urine-based biomarker tests to predict PASC and post-COVID risks. The study included data from Crit-CoV-U and interviews with 27 PASC patients, which showed difficulties in everyday life and gender differences. PASC is associated with reduced quality of life and higher costs for healthcare and society. The results support early risk assessment, personalized care and better health policies.

External links

UriCoV (URInary peptidomic patterns of Long-COVID syndrome)